GSK Agrees to Settle Flonase Antitrust Actions for $195 Mil.

, The Legal Intelligencer


Drugmaker GlaxoSmithKline has agreed to settle with plaintiffs for a total of $195 million over allegations that it monopolized the market for its nasal spray Flonase.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

  • RD Legal Funding

    This is a great win for the plaintiffs involved. There have been a rash of companies that have settled lawsuits that have to do with these kinds of issues. This seems like a regular settlement in these kinds of situations except there are deeper consequences because of drugs.

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202581978415

Thank you!

This article's comments will be reviewed.